Next generation of the industry-leading Cyto-Mine® platform offers new capabilities to optimize single-cell analysis workflows
Opens up new, multiplexed assays and applications for antibody discovery and cell line development, and allows entry into new markets such as cell and gene therapy
Cyto-Mine® Chroma, the next-generation single-cell analysis platform, integrates multiplexed assays to enhance the speed and precision of biologics discovery and development.
Cambridge, UK, [1 October 2024]: Sphere Bio, a leading provider of innovative droplet-based microfluidics solutions for single-cell analysis and isolation, today shared details of Cyto-Mine® Chroma, the second generation of its flagship Cyto-Mine platform. This new platform will offer enhanced capabilities, including multiplexing and greater assay flexibility, to further maximize the efficiency and precision of single-cell functional analysis workflows.
Cyto-Mine® Chroma builds on the original Cyto-Mine® platform’s ability to leverage picodroplet technology to encapsulate single cells, assess cellular function, and isolate target cells for downstream expansion or analysis. The new Chroma system will maintain Cyto-Mine®’s best-in-class throughput enabling functional screening of millions of cells per hour and expand its multiplexing capabilities. With the upgrade to a four-color laser and detector system, Cyto-Mine® Chroma significantly expands the utility of the original, single-laser Cyto-Mine® platform by increasing the number of targets that can be analyzed for each encapsulated cell.
Richard Hammond CTO, Sphere Bio
“We have built Chroma to enable the continuous expansion of its capabilities – providing our team with the ultimate platform to leverage as we respond to customers’ evolving needs.”
Launching in conjunction with the company’s first multiplexed assay kit, the platform will enable researchers to conduct multiplexing in a single droplet, improving the throughput and precision of clone selection, by analyzing single cells for viability, productivity, and target specificity in one step. By accelerating the early selection of superior candidate cells, overall project timelines are reduced from months to weeks, while reducing effort and cost. “By combining multiplexing with our best-in-class cell throughput for functional screening of viable cells, the Cyto-Mine® Chroma platform will be a powerful new tool for our customers and will help them shave months off their project timelines.” Richard Hammond.
Cyto-Mine® Chroma, which launches in Q1, 2025, is designed to support evolving needs in single cell analysis, facilitating cutting-edge, cost-effective research across broad applications, including antibody discovery, cell line development, and emerging areas such as cell therapy. Sphere Bio’s product roadmap includes a wide range of new assays and applications that can be developed on the platform, and the capacity for extended capabilities to be added via upgrade modules.
Dale Levitzke, CEO, Sphere Bio, commented:
“We have developed Cyto-Mine® Chroma to revolutionize functional single-cell screening workflows – it marks a significant milestone as part of our long-term vision for success and leadership in the single-cell analysis field. The new Chroma system is a direct result of working closely with our customers to understand their requirements and how our microfluidic technologies can best support these, now and in the future. Cyto-Mine® Chroma will strengthen our presence in the market and open opportunities for innovation and expansion, including entry into new, high growth markets globally.”
For information contact:
Dr Claire Cox
Sphere Bio Ltd.
Tel: +44 (0)7365 209 441
Email: claire.cox@spherebio.com
Zyme Communications
Lily Jeffery
Tel: +44 (0)7891 477 378
Email: lily.jeffery@zymecommunications.com
About Sphere Bio
Sphere Bio develops and manufactures single cell analysis and monoclonality assurance systems to enable researchers to find, analyze and isolate the most valuable cells, with ease and speed.
Sphere Bio’s proprietary picodroplet microfluidic platforms are designed specifically for single-cell screening and isolation, allowing users to encapsulate and analyze single cells within a picodroplet, while maintaining viability. Harnessing this technology, the Company’s range of novel microfluidic tools facilitate leading-edge research and accelerate biotherapeutic discovery and development, cell therapy, and synthetic biology workflows, streamlining the journey of discovery in labs, globally.
Sphere Bio is based at Granta Park in Cambridgeshire (UK). The Company has also internationalized its business via a global network of distributors.
For more information contact:
